Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00676-0 · Cited by 1,983

Interleukin-6 receptor antagonists in critically ill patients with Covid-19.

The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Salama, C., Han, J., Yau, L., Reiss, W. G., Krämer, B., Neidhart, J. D., Criner, G. J., Kaplan‐Lewis, E., Baden, R. P., Pandit, L. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2030340 · Cited by 1,306

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

Hermine, O., Mariette, X., Tharaux, P.-L., Resche-Rigon, M., Porcher, R., Ravaud, P., CORIMUNO-19 Collaborative Group, Bureau, S., Dougados, M., Tibi, A., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6820 · Cited by 734

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia

Salvarani, C., Dolci, G., Massari, M., Merlo, D. F., Cavuto, S., Savoldi, L., Bruzzi, P., Boni, F., Braglia, L., Turrà, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6615 · Cited by 696

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Abaleke, E., Abbas, M. A., Abbasi, S., Abbott, A., Abdelaziz, A., Abdelbadiee, S., Abdelfattah, M., Abdul, B., Rasheed, A. A., Kadir, R. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00149-5 · Cited by 561

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trialPreprint

Horby, P., Campbell, M., Staplin, N., et al. (2021) · medRxiv · doi:10.1101/2021.02.11.21249258 · Cited by 286

COVID-19 en receptores de trasplante renal: ¿qué hemos aprendido tras 18 meses de pandemia?

Fernández‐Ruiz, M. (2021) · Enfermería Nefrológica · doi:10.37551/s2254-28842021020

COVID-19 and Cardiovascular System. Part 3. COVID-19 Current Treatment Approaches: Evidence-Based Review

Vasilchenko, M. K., Ivannikov, A. A., Esaulenko, A. N., Алиджанова, Х. Г., & Petrikov, S. S. (2021) · Russian Sklifosovsky Journal Emergency Medical Care · doi:10.23934/2223-9022-2021-10-3-438-451

Clinical trials during the COVID-19 pandemic: research design and lessons

Abo-Leyah, H., & Chalmers, J. D. (2021) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005521

A Clinical Update on Employing Tocilizumab to Fight COVID-19

Dhara, N., Saha, S., & Chatterjee, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.99785

The authors reply

Dellinger, R. P., Levy, M. M., Schorr, C., & Townsend, S. R. (2022) · Critical Care Medicine · doi:10.1097/ccm.0000000000005406

新型コロナウイルス感染症―治療戦略とワクチンについて―

建部, 将., & 瀬尾, 龍. (2022) · Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) · doi:10.3950/jibiinkotokeibu.125.3_243

Current Updates on Covid-19 Vaccine Research and an Overview of Therapeutic Drug Research

Oviyaasri, O., Manjuladevi, M., Kalaiselvan, S., & Haripriyan, U. (2021) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/2930

EFFICACY OF REMDESIVIR VERSUS REMDESIVIR PLUS TOCILIZUMAB IN MODERATE TO SEVERE COVID-19 PATIENTS ADMITTED IN THE CRITICAL CARE UNIT OF A TERTIARY CARE HOSPITAL IN WEST BENGAL, INDIA

Ray, M., Kundu, A. K., Lahiri, G., & Lahiri, G. (2022) · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · doi:10.36106/ijsr/8606340

Does Tocilizumab Influence the Outcome of Patients with COVID-19 Pneumonia Compared to the Standard Therapy? Retrospective Analysis of Data Obtained during Phase I COVID Pandemic

Mohamed, M. E., Farouk, K., Mohamed, G. A., Ahmed, A., Mohamed, A., Sameh, S. T., Amr, H. A. E. B., & Motaz, M. E. (2022) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2022.9476

Tocilizumab as a breakthrough in the cytokine storm of COVID-19 pneumonia- Case series in the intensive care unit

Gulabani, M., Chauhan, R., & Saxena, A. K. (2022) · Indian Journal of Clinical Anaesthesia · doi:10.18231/j.ijca.2022.076

The Role of VV-ECMO in Severe COVID-19 ARDS

MacDonncha, C., Jooste, R., Laffey, J. G., & Hanley, C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107047

V. Current Treatment Approach for COVID-19

Kutsuna, S. (2021) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.110.2374

The Renin Angiotensin System at the Time of COVID-19

Grote, K., Kreutz, J., Schaefer, A.-C., Markus, B., & Schieffer, B. (2023) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-14952-8_9

Resultados en la práctica asistencial y coste marginal del tratamiento con tocilizumab en pacientes COVID-19

Molina, A. G., & Alós-Almiñana, M. (2023) · Farmacia Hospitalaria · doi:10.1016/j.farma.2022.12.003

Comparison of clinical outcomes of intensive care patients with COVID-19 pneumonia receiving and not receiving tocilizumab treatment

Dal, H., Keklik, E. S. K., Dağtekin, G., Yaman, E., Pehlivanoğlu, P., Çimen, M., DİKER, S., Avcil, M., & Avcı, S. (2023) · Anatolian Current Medical Journal · doi:10.38053/acmj.1198167

Proteomic understanding of SARS-CoV-2 infection and COVID-19: Biological, diagnostic, and therapeutic perspectives

Al‐Ejeh, F., Merhi, M., Al-Muftah, M., Fernandes, Q., Al-Zaidan, L., Bedhiafi, T., Mestiri, S., Moustafa, D., Taib, N., Inchakalody, V. P., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91794-0.00002-0

[Translated article] Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients

Molina, A. G., & Almiñana, M. A. (2023) · Farmacia Hospitalaria · doi:10.1016/j.farma.2022.12.014

Pulmonary Manifestations of COVID-19

Nagaraju, S., Ramalingam, S., & Mani, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87539-4.00005-1

The effectiveness of Tocilizumab in severe covid 19 pneumonia among critically ill patients

Rajachandran, K., Varghese, G. S., & Kumar, J. V. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00130

Tocilizumab Associated With Survival in Patients Hospitalized for COVID-19 Acute Respiratory Distress Syndrome and Low Urine Output

Fadel, R. A., Scott, A., Parsons, A. J., Murskyj, I., Nasiri, N., Sayf, A. A., & Ouellette, D. R. (2023) · Journal of Intensive Care Medicine · doi:10.1177/08850666231180528

A Systematic Review with Meta-Analysis and Indirect Comparison of the Effectiveness of COVID-19 Anti-Interleukin Therapy

Gomon, Y. М., Колбин, А. С., Fakhrutdinova, A. M., Usmanova, T. A., Sultanova, F. М., & Balykina, Y. Е. (2023) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2023-68-3-4-52-65

Impact of early tocilizumab administration on the progression of respiratory failure in COVID-19 patients

Мержоева, З. М., Yaroshetskiy, A. I., Savko, S. A., Krasnoshchekova, A. P., Аркадьевна, М. И., Tsareva, N. A., Трушенко, Н. В., Nuralieva, G. S., & Avdeev, S. N. (2023) · PULMONOLOGIYA · doi:10.18093/0869-0189-2023-33-4-472-487

Clinical characteristics, management, and prevention of coronavirus disease 2019

Guan, W., & He, J. (2023) · Frigid Zone Medicine · doi:10.2478/fzm-2023-0019

Viral Infection

Tatara, A. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-39474-4_8

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19

Ivashkin, V. T., Maslennikov, R. V., Vasilieva, E. V., Chipurik, M., Semikova, P., Semenets, V. V., & Russkova, T. (2023) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2023-33-5-54-64

Some reflections on immunosuppressants and their delivery to the lungs by aerosol in the treatment of COVID-19

Kobylyansky, V. I. (2023) · Medical Immunology (Russia) · doi:10.15789/1563-0625-sro-2613

The effect of levilimab on the clinical presentations and changes in inflammatory biomarkers in outpatients with mild to moderate COVID-19

Nizhenko, T. N., Ших, Е. В., Sizova, Z. M., Drozdov, V. N., Лапидус, Н. И., & Евгеньевна, П. А. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-201

COVID-associated endotheliitis

Melkumyants, A. M., & Buryachkovskaya, L. I. (2024) · doi:10.18093/978-5-6048754-6-9-2024-2-461-474

Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19

Michot, J., Dozio, V., Rohmer, J., Pommeret, F., Roumier, M., Yu, H., Sklodowki, K., Danlos, F. X., Ouali, K., Kishazi, E., et al. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00422

Adrenal Infarction - An Early and Late Complication of COVID-19: A Case Report

Gigi, M., Kebadze, K., Beriashvili, M., Dvaladze, M., Vardosanidze, E., ABULADZE, A., Gigolashvili, T., & Modebadze, M. (2024) · Health & Medical Sciences · doi:10.47134/phms.v2i2.310

Surge of healthcare associated infections in COVID intensive care units

Priyadarshi, K., Dhandapani, S., Benedict Vinothini, A., Punnen, S. A., & Sastry, A. S. (2024) · Indian Journal of Microbiology Research · doi:10.18231/j.ijmr.2024.051

Integrating Multiple Deep Learning Models for Disaster Description in Low-Altitude Videos

Wang, H. (2022) · doi:10.12794/metadc2048642

Outcomes of Severe Covid-19 Among Patients Who Did and Did Not Receive Tocilizumab: A Two-year Prospective Cohort StudyPreprint

Beronja, B., Gazibara, T. M., Stevanović, O., Nikolić, N., Todorović, N., Filipović, A., Simić, J., Lukić, B., Hristović, D., Karan, A., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-5821416/v1

Unravelling the Potential of Anticancer Drugs for SARS-CoV-2

Low, Z. Y., Wong, K. H., Yip, A. J. W., Liew, H. L., Farouk, I. A., Lal, S. K., & Choo, W. S. (2025) · Current Pharmacology Reports · doi:10.1007/s40495-025-00390-6

THE ROLE OF TOCILIZUMAB IN TREATMENT OF COVID-19

Gradek, A., Sawczuk, M., Nowak, D., Zarzycki, A., Tarnowska, J. A., Szydzik, F., Żegleń, B., Kozon, K., Grudzień, M., & Macuk, P. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3484

Caractérisation des activités antivirales des anticorps anti-VIH-1 et anti-SARS-CoV-2

Dufloo, J. (2021) · theses.fr (ABES) · doi:10.70675/215798eaz7f82z4e57za8eazf4453d37b8c8

Identification of Biomarkers Associated With the Combination of Immunotherapy and Anti-Angiogenic Drugs in the Treatment of Mesothelioma : Translational Analyses of the PEMBIB Clinical Trial Combining the Anti-PD1 Monoclonal Antibody Embrolizumab and the Anti-Angiogenic Tyrosine Kinase Inhibitor Nintedanib

Danlos, F. (2021) · theses.fr (ABES) · doi:10.70675/ff8cb58bzc391z43f8zbd32zc8c4b2cdc725

Application of Multivariate Gaussian Convolution and Mixture Models for Identifying Key Biomarkers Underlying Variability in Transcriptomic Profiles and the Diversity of Therapeutic Responses

Chassagnol, B. (2023) · theses.fr (ABES) · doi:10.70675/52e5031azbec1z427azadafzf0cbf809a35e

Integration of various types of information in living systematic reviews

Davidson, M. (2024) · theses.fr (ABES) · doi:10.70675/a60f5802z1fb9z4866z9e22z7be74c96be25

Influence of obesity on susceptibility to systemic symptoms and host responses to orthoflaviviral infection: a prospective observational study using yellow fever vaccine to simulate acute infection

Syenina, A., Tham, C. Y. L., Tng, D. J., Chew, V. S. Y., Yee, J. X., Leong, Y. S., Hamis, N. Z., Tan, H. C., Joon, H. Y., Chan, J. T., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106290

Analysis of Serial C-Reactive Protein Levels in Critically Ill COVID-19 Patients Receiving Tocilizumab

Masood, A., Farooq, O., Waris, S., Khan, M. Z., Mumtaz, A., Aslam, M., & Usama, M. (2020) · BIOMEDICA · doi:10.24911/biomedica/5-132 · Cited by 1

Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone

Calderón-Ochoa, C., Plamenov-Donchev, N., Hernández-Quiñones, F., Mendoza-López, O., Hinojos-Gallardo, L. C., Longino-Gómez, A. J., Hernández-Saldaña, R., Duque-Rodríguez, J., & Ishida-Gutiérrez, M. C. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.02498-23 · Cited by 3

Tocilizumab in hospitalized patients with COVID‐19: Clinical outcomes, inflammatory marker kinetics, and safety

Hill, J. A., Menon, M. P., Dhanireddy, S., Wurfel, M. M., Green, M., Jain, R., Chan, J. D., Huang, J., Bethune, D., Turtle, C. J., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26674 · Cited by 33

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019

Price, C. C., Altice, F. L., Shyr, Y., Koff, A., Pischel, L., Goshua, G., Azar, M. M., McManus, D. S., Chen, S., Gleeson, S. E., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.06.006 · Cited by 204

Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study

Martínez‐Sanz, J., Muriel, A., Ron, R., Herrera, S., Pérez-Molina, J. A., Moreno, S., & Villar, S. S. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.09.021 · Cited by 105